Bioactive glasses with tuned ion releasing capability as versatile biomaterials for tissue engineering
Biography: Aldo R. Boccaccini is Professor and Head of the Institute of Biomaterials at University of Erlangen-Nuremberg, Germany. He is also visiting Professor at Imperial College London, UK. He holds a nuclear engineering degree from Instituto Balseiro (Argentina), Dr-Ing. (PhD) from RWTH Aachen University (Germany) and Habilitation from Technical University of Ilmenau (Germany). Prior to his current position, he spent 10 years at Imperial College London, Department of Materials, as Lecturer, Reader and Professor of Materials Science. He has held post-doctoral positions at University of Birmingham (UK) and University of California, San Diego (USA). He was Head of the Department of Materials Science and Engineering in Erlangen (2017-2019). The research activities of Prof. Boccaccini are in the field of ceramics, glasses and composites for biomedical, functional and/or structural applications. He is the author or co-author of more than 900 scientific papers and 25 book chapters. His work has been cited more than 44,000 times (h = 93, Scopus®, h= 110, Google Scholar®) and he was included in the “Highly cited researchers” lists in 2018 (Clarivate Analytics) and 2014 (Thomson Reuter). He is the Editor-in-Chief of the journal “Materials Letters” (Elsevier), founding Editor and Editor-in-Chief of the journal “Biomedical Glasses” and serves in the editorial board of more than 10 international journals. Boccaccini has been a visiting professor at different universities around the world. He is a Fellow of the Institute of Materials, Minerals and Mining (IOM3) (UK), the American Ceramic Society, the Society of Glass Technology (UK) and the European Ceramic Society. His achievements have been recognized with several awards including the Materials Prize of the German Materials Society (DGM) in 2015, the Turner Award of International Commission on Glass (2016) and Friedberg Lecture Award (2016) of American Ceramic Society. Boccaccini is also an elected member of the World Academy of Ceramics and of the National Academy of Engineering and Applied Sciences of Germany (acatech) and advisor to the Science and Technology Ministry of Argentina. Boccaccini serves in the Executive Committee of the Federation of European Materials Societies (FEMS) representing the German Materials Society and he has been a member of the Council of the European Society for Biomaterials (ESB) since 2015. Boccaccini has served in several review panels of the European Research Council (ERC) and of the German Research Foundation (DFG) (2011-2020)
Automation of the biomaterials discovery process
Biography: Jan de Boer studied biology at the University of Utrecht and obtained his PhD in the lab of Jan Hoeijmakers at the Erasmus MC Rotterdam on mouse models for premature ageing in 1999. After a postdoc at the MRC Laboratory of Molecular Biology in Cambridge, UK, he started as a research associate at IsoTis B.V. where his research focused on bone tissue engineering, which was continued as associate professor at the University of Twente and as full professor at the University of Maastricht. Since 2018, he is chair of the BioInterface Science lab at the Institute for Complex Molecular Systems and the department of Biomedical Engineering at Eindhoven University of Technology.
Jan studies the molecular complexity of cells and how molecular circuits are involved in cell and tissue function. With a background in mouse and Drosophila genetics, he entered the field of biomedical engineering in 2002 and has since focused on understanding and implementing molecular biology in the field of tissue engineering, regenerative medicine and medical devices interface biology. His research is characterized by a holistic approach to both discovery and application, aiming at combining high throughput technologies, computational modeling and experimental cell biology to streamline the wealth of biological knowledge to real clinical applications.
He is former chair of the Netherlands Society for Biomaterials and Tissue Engineering, CSO and co-fo
under of Materiomics b.v., co-founder of the MosaCell scientific platform and co-founder of the Merln Institute for Technology-inspired Regenerative Medicine.
Instructive biomaterials for skeletal tissue regeneration
Biography: Pamela Habibovic obtained her PhD degree in 2005 from the University of Twente. In 2006, she worked as post-doctoral research fellow at Children’s Hospital Boston-Harvard Medical School and in 2007 she spent a year as post-doctoral research fellow at McGill University in Montreal, Canada. From 2008 until 2014 she led a research group at the University of Twente, first as assistant and later as associate professor. In 2014, she moved to Maastricht University, where she became Full Professor of Inorganic Biomaterials and where she cofounded MERLN Institute for Technology-Inspired Regenerative Medicine. Currently, she is the Scientific Director of the institute and she chairs the Department of Instructive Biomaterials Engineering. The main focus of her research group is on synthetic bone graft substitutes, bioinorganics, nanomaterials for theranostics in regenerative medicine and high-throughput approaches in biomaterials research. For her research she received prestigious Veni, Vidi, Aspasia and Gravitation grants of the Netherlands Organisation for Scientific Research among other external research funds. Since 2013, she serves as a council member of the European Society for Biomaterials (ESB), and since 2017 she holds the role of the ESB President. Habibovic is an Associate Editor of the RSC journal Biomaterials Science and an editorial board member of the journals Acta Biomaterialia, Journal of Materials Science: Materials in Medicine, Advanced Biomaterials and Devices in Medicine, Regenerative Biomaterials, Biomedical Engineering and Biomaterials Research. She has published over 80 peer-review articles on the topic of biomaterials and regenerative medicine. In 2013, she received the Jean Leray Award of the European Society for Biomaterials.
Human skeletal stem cells: in vivo targeting to enhance bone formation
Biography: Professor Moustapha Kassem is a Professor of Molecular Endocrinology, University of Southern Denmark, Odense, Professor and Chief Physician, Department of Endocrinology, University Hospital of Odense and Adjunct professor of Stem Cell Biology, Danish Stem Cell Center (DanStem), Faculty of Health Sciences, University of Copenhagen, Denmark.
Dr Kassem main research focus is studying mechanisms of impaired bone formation and bone fragility during aging and in osteoporosis as well as molecular mechanisms of osteoblast (bone forming cells) differentiation of human skeletal (mesenchymal) stem cells (MSC); studying the phenomenon of biological aging of MSC with respect to lineage fate determination and how the cellular senescent phenotype can be overcome by genetic and non-genetic approaches. Dr Kassem is studying the possible clinical use of MSC in tissue regeneration in a variety of diseases including fracture healing. Dr Kassem has published 244 original papers and 74 Invited reviews/book chapters in the field of stem cell biology and osteoporosis pathophysiology. Dr Kassem is the recipient of 2020 Louis Avioli Founder Award from the American Society for Bone and Mineral Research.
Vascularized composite tissue engineering (VCE): First steps towards a new frontier in regenerative Surgery
Biography: Born in Brussels in 1962, Benoit Lengelé is Professor of Human Anatomy at UCLouvain and head of the Plastic & Reconstructive Surgery department at St Luc Hospital, Brussels. Through the dramatic condition of disfigurement, he studied the functional relationship between the brain and the cephalic extremity and also questioned the symbolic meaning of the human face as a vector of identity. In 2005, he carried out in Amiens, France, the first face transplantation ever. This groundbreaking procedure was regarded a worldwide scientific event and gave rise to a huge public debate. It is now accepted by peers, but the lifespan of Vascularized Composite Allografts ( VCAs) seems to be limited to 10-15 years, due to chronic vascular rejection. Therefore, the current research in B. Lengelé’s Lab is now focused on Vascularized Composite Engineering (VCE), another concept he pioneered with his team. Member of numerous scientific and academic societies, he is the author of 148 peer-papers and chapters of books. He received numerous scientific prizes and international awards. In 2019, he was made Doctor Honoris Causa of the university of Amiens and received the Knight’s cross of the legion of honor. HM King Albert II of Belgium granted him hereditary nobility and appointed him as his personal surgeon in 2011.
Understanding microglia and macrophage immune responses during neuroinflammatory events: moving from animal models to murine and human iPSC-derived 2D and 3D neuro-immune cell culture models.
Biography: Peter Ponsaerts is Professor within the Laboratory of Experimental Hematology at the University of Antwerp, where his team has a strong expertise in advanced embryonic/adult stem cell culture and genetic engineering, stem cell transplantation in rodent models of neuro-inflammation, fluorescent animal models, flow cytometric monitoring of immune responses, in vivo bio-imaging and quantitative histological analyses. The main research questions his team addresses are whether and how immunomodulating cell or gene therapeutic approaches can influence both microglia and macrophage immune responses during inflammatory events in the central nervous system. These topics are experimentally investigated in vivo using animal models for multiple sclerosis, spinal cord injury and stroke, as well as in vitro using iPSC-derived 2D and 3D neuro-immune cell culture models. He published 90 peer-reviewed publications (WoS citations: 2752, WoS H-index: 29). As promotor, co-promotor or mentor, he supervised 15 doctorates defended at UA, and is currently promotor of 6 ongoing doctorates at UA. His research efforts resulted in one patent application: “Improved transfection of eukaryotic cells with linear polynucleotides by electroporation” His academic teaching duties include the following courses: Medical Cell Biology: including Stem Cell Biology (1st master students), Scientific Reporting (2nd bachelor students), Biochemistry (2nd bachelor students) and Immunology (3rd bachelor students).
From Molecules to the Clinic – Austrian Cluster for Tissue Regeneration (ACTR)
Biography: Heinz Redl has a background in biochemistry with almost 40 years’ experience in trauma and regenerative medicine research. He was the director of the Ludwig Boltzmann Institute of Experimental and Clinical Traumatology within the main trauma research center of AUVA (1998-2019) representing 7 trauma and 4 rehabilitation centers and holds the position of Associated Professor at the Technical University Vienna, Institute for Chemical Engineering, plus adjunct Professor at the University of Texas, Medical Branch at Galveston and at the Medical University of Vienna. He coordinates the Austrian Cluster for Tissue Regeneration since 2006, which includes 28 work groups from academia with multiple research targets and 12 spin-off groups. In 1998 he founded the company Trauma Care Consult, which is specialized on preclinical research and assists products registration at FDA and EMA. In 2014 he co-founded the spin-off company Liporegena and in 2017 MorphoMed. Prof. Redl organized many conferences in the field of regenerative medicine such as the World Congress for Tissue Engineering and Regenerative Medicine (TERMIS 2012) and many annual workshops (Winterschool Radstadt and Wiggers Bernhard series). He holds positions in several societies, such as Past-Chair of TERMIS-EU and is member of multiple editorial boards (e.g. Tissue Eng., J.TERM, J. Eur Cells Mat.). He is editor in Chief of the updatable book series Springer/TERMIS “Tissue Engineering and Regeneration”. His expertise includes experience in different fields of tissue regeneration: he is co-developer of the fibrin sealant system, developer of surgical devices in current clinical use and had many collaboration projects with major industry partners. He has co-authored 580 Pubmed papers and holds > 15 patents/patent submissions.